How Many Adults with Private Health Insurance Could Use GLP-1 Drugs More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis
Weight trends: Is it moving, or is it truly stalled
thyroid tumors and cancer One of the serious long-term side effects of Wegovy is the possibility of thyroid tumors, including cancer
The body adapts receptor expression patterns to consistent external signals
The shift is a blow to Novo Nordisk, already under pressure from Eli Lilly's rival drugs and from gray-market compounded versions in the US
Many people inject on Friday evenings for this reason If nausea persists beyond the first two weeks at a given dose, or if it is severe enough to prevent eating, contact your provider